Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable,” suggesting that there could be a shift in fund flows towards different ...

Donald Trump's nominees have the vision and real-world skills required to achieve financial success in business and now bring it to the job for the American people.

Cantor Fitzgerald董事长兼美国商务部长提名人Howard Lutnick因该金融公司对全球最大稳定币USDT发行方Tether的投资问题，面临参议院民主党人的质询。 此次听证会于1月29日在参议院商务、科学和运输委员会举行，在此之前一天，Lutnick已在参议院银行委员会作证。

On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating. Trading at $11.49, ORIC has seen analyst targets ranging from ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Surgery Partners (NASDAQ:SGRY) with a steady price target of $36.00. The stock, which has shown significant momentum with a 20% ...

As previously reported last night, Cantor Fitzgerald initiated coverage of five Government Technology & Space, or “GovTech,” stocks, starting SAIC (SAIC) with a Neutral rating and $120 price ...

“As you can imagine, the pain we suffered with Gary and 657 of my other friends and colleagues at Cantor Fitzgerald were killed on 9/11,” Lutnick said during his confirmation hearing before ...

In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Proto Labs (PRLB – Research Report), with a price target of $50.00. The company’s shares closed ...

Cantor Fitzgerald Equity Opportunity Fd earns a Low Process Pillar rating. The main driver of the rating is the fund's weak long-term risk-adjusted performance. This can be seen in its five-year ...

On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...